Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysisHuseyin Naci, Christopher M. Booth, Courtney Davis et al.|BMJ|2019Cited by 242
Evolution of the Randomized Clinical Trial in the Era of Precision OncologyJoseph C. Del Paggio, Christopher M. Booth, Vinay Prasad et al.|JAMA Oncology|2021Cited by 200
Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional surveyAdam Fundytus, Christopher M. Booth, Manju Sengar et al.|The Lancet Oncology|2021Cited by 170
An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on AccessNatasha B. Leighl, Bishal Gyawali|American Society of Clinical Oncology Educational Book|2021Cited by 167
An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income CountriesJ. Connor Wells, Christopher M. Booth, Shubham Sharma et al.|JAMA Oncology|2021Cited by 165